Blood Res.  2022 Jun;57(2):106-116. 10.5045/br.2022.2021227.

Multidisciplinary supportive care in systemic light chain amyloidosis

• Maroun BZ
• Allam S
• Chaulagain CP

• KMID: 2530874
• DOI: http://doi.org/10.5045/br.2022.2021227

Abstract

The immunoglobulin light-chain amyloidosis is a multisystemic disease which manifests by damage to the vital organs by light chain-derived amyloid fibril. Traditionally, the treatment has been directed to the underlying plasma cell clone with or without high dose chemotherapy followed by autologous stem cell transplantation using melphalan based conditioning. Now with the approval of highly tolerable anti-CD38 monoclonal antibody daratumumab based anti-plasma cell therapy in 2021, high rates of hematologic complete responses are possible even in patients who are otherwise deemed not a candidate for autologous stem cell transplantation. However, despite the progress, there remains a limitation in the strategies to improve symptoms particularly in patients with advanced cardiac involvement, those with nephrotic syndrome and autonomic dysfunction due to underlying systemic AL amyloidosis. The symptoms can be an ordeal for the patients and their caregivers and effective strategies are urgently needed to address them. The supportive care is aimed to counteract the symptoms of the disease and the effects of the treatment on involved organs’ function and preserve patients’ quality of life. Here we discuss multidisciplinary approach in a system-based fashion to address the symptom management in this dreadful disease. In addition to achieving excellent anti-plasma cell disease control, using treatment directed to remove amyloid from the vital organs can theoretically hasten recovery of the involved organs thereby improving symptoms at a faster pace. Ongoing phase III clinical trials of CAEL-101 and Birtamimab will address this question.

Keyword

Supportive care; Multidisciplinary approach; Hematology; Amyloidosis; Light chain

Figure

• 

  Fig. 1 Perivascular amyloid deposits demonstrated as apple green birefringence under polarized light in this Congo Red stain specimen from a patient with systemic AL amyloidosis due to lymphoplasmacytic lymphoma (Bone marrow Congo Red, ×20).

• 

  Fig. 2 An electrocardiogram (EKG) showing pseudo-infarction pattern or Q-waves in chest Leads V1-V3 in this 62-year-old man presenting with AL cardiomyopathy from underlying clonal plasma cell neoplasms. Both limb and chest lead also demonstrate presence of low voltage.

• 

  Fig. 3 One of the cutaneous manifestations of systemic AL amyloidosis include amyloid purpura. Amyloid purpura is non-blanching purpuric relapsing and remitting skin lesions usually involving the peri-orbital skin, the upper trunk and neck. The purpura can break and cause oozing, skin breakdown and significant pain. A marked thinning of skin and skin breakdown needing local care (for oozing and bleeding) is seen in the picture.

Reference

1. Cook J, Muchtar E, Warsame R. 2020; Updates in the diagnosis and management of AL amyloidosis. Curr Hematol Malig Rep. 15:155–67. DOI: 10.1007/s11899-020-00574-5. PMID: 32394186.

2. Ryšavá R. 2019; AL amyloidosis: advances in diagnostics and treatment. Nephrol Dial Transplant. 34:1460–6. DOI: 10.1093/ndt/gfy291. PMID: 30299492.

3. Gertz MA. 2018; Immunoglobulin light chain amyloidosis: 2018 update on diagnosis, prognosis, and treatment. Am J Hematol. 93:1169–80. DOI: 10.1002/ajh.25149. PMID: 30040145.

4. Quock TP, Yan T, Chang E, Guthrie S, Broder MS. 2018; Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood Adv. 2:1046–53. DOI: 10.1182/bloodadvances.2018016402. PMID: 29748430. PMCID: PMC5965052.

5. Joseph NS, Kaufman JL. 2018; Novel approaches for the management of AL amyloidosis. Curr Hematol Malig Rep. 13:212–9. DOI: 10.1007/s11899-018-0450-1. PMID: 29951831.

6. Cibeira MT, Ortiz-Pérez JT, Quintana LF, Fernádez de Larrea C, Tovar N, Bladé J. 2020; Supportive care in AL amyloidosis. Acta Haematol. 143:335–42. DOI: 10.1159/000506760. PMID: 32235118.

7. Wong SW, Fogaren T. 2020; Supportive care for patients with systemic light chain amyloidosis. Hematol Oncol Clin North Am. 34:1177–91. DOI: 10.1016/j.hoc.2020.08.007. PMID: 33099432.

8. Khouri J, Anwer F, Samaras CJ, et al. 2020; Safety, tolerability and efficacy of Cael-101 in AL amyloidosis patients treated on a phase 2, open-label, dose selection study to evaluate the safety and tolerability of Cael-101 in patients with AL amyloidosis. Blood (ASH Annual Meeting Abstracts). 136(Suppl):21. DOI: 10.1182/blood-2020-137235.

9. Gertz MA, Landau H, Comenzo RL, et al. 2016; First-in-human phase I/II study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction. J Clin Oncol. 34:1097–103. DOI: 10.1200/JCO.2015.63.6530. PMID: 26858336. PMCID: PMC5470113.

10. Rubin J, Maurer MS. 2020; Cardiac amyloidosis: overlooked, underappreciated, and treatable. Annu Rev Med. 71:203–19. DOI: 10.1146/annurev-med-052918-020140. PMID: 31986086.

11. Falk RH, Alexander KM, Liao R, Dorbala S. 2016; AL (light-chain) cardiac amyloidosis: a review of diagnosis and therapy. J Am Coll Cardiol. 68:1323–41. DOI: 10.1016/j.jacc.2016.06.053. PMID: 27634125.

12. Bhogal S, Ladia V, Sitwala P, et al. 2018; Cardiac amyloidosis: an updated review with emphasis on diagnosis and future directions. Curr Probl Cardiol. 43:10–34. DOI: 10.1016/j.cpcardiol.2017.04.003. PMID: 29173805.

13. Kumar S, Dispenzieri A, Lacy MQ, et al. 2012; Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 30:989–95. DOI: 10.1200/JCO.2011.38.5724. PMID: 22331953. PMCID: PMC3675680.

14. Dispenzieri A, Gertz MA, Kyle RA, et al. 2004; Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 22:3751–7. DOI: 10.1200/JCO.2004.03.029. PMID: 15365071.

15. Muchtar E, Gertz MA, Kumar SK, et al. 2018; Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use? Amyloid. 25:86–92. DOI: 10.1080/13506129.2018.1449744. PMID: 29529877. PMCID: PMC7433245.

16. Ashraf I, Peck MM, Maram R, et al. 2020; Association of arrhythmias in cardiac amyloidosis and cardiac sarcoidosis. Cureus. 12:e9842. DOI: 10.7759/cureus.9842. PMID: 32953349. PMCID: PMC7497218.

17. Feng D, Syed IS, Martinez M, et al. 2009; Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis. Circulation. 119:2490–7. DOI: 10.1161/CIRCULATIONAHA.108.785014. PMID: 19414641.

18. Ton K, Watts J, Malhotra R, et al. 2011; Predictors of survival to orthotopic heart transplant in patients with immunoglobulin light chain amyloid cardiomyopathy. Circulation. 124(Suppl):A18160.

19. Palladini G, Kastritis E, Maurer MS, et al. 2020; Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood. 136:71–80. DOI: 10.1182/blood.2019004460. PMID: 32244252. PMCID: PMC7332897.

20. Griffin JM, Chiu L, Axsom KM, et al. 2020; Outcomes after heart transplantation for AL compared to ATTR cardiac amyloidosis. Clin Transplant. 34:e14028. DOI: 10.1111/ctr.14028. PMID: 32623785. PMCID: PMC7744118.

21. Qualls DA, Lewis GD, Sanchorawala V, Staron A. 2019; Orthotopic heart transplant rejection in association with immunomodulatory therapy for AL amyloidosis: a case series and review of the literature. Am J Transplant. 19:3185–90. DOI: 10.1111/ajt.15499. PMID: 31207062.

22. Kyle RA, Gertz MA. 1995; Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 32:45–59. PMID: 7878478.

23. Palladini G, Milani P, Foli A, et al. 2014; Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients. Leukemia. 28:2311–6. DOI: 10.1038/leu.2014.227. PMID: 25059496.

24. Roussel M, Merlini G, Chevret S, et al. 2020; A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis. Blood. 135:1531–40. DOI: 10.1182/blood.2019004369. PMID: 32108228.

25. Palladini G, Sachchithanantham S, Milani P, et al. 2015; A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood. 126:612–5. DOI: 10.1182/blood-2015-01-620302. PMID: 25987656.

26. Lee T, Biddle AK, Lionaki S, et al. 2014; Personalized prophylactic anticoagulation decision analysis in patients with membranous nephropathy. Kidney Int. 85:1412–20. DOI: 10.1038/ki.2013.476. PMID: 24336031. PMCID: PMC4040154.

27. Gentile G, Remuzzi G, Ruggenenti P. 2015; Dual renin-angiotensin system blockade for nephroprotection: still under scrutiny. Nephron. 129:39–41. DOI: 10.1159/000368331. PMID: 25531311.

28. Yeh CT, Tseng HS, Liu WS, Li SY, Yang WC, Ng YY. 2012; Severe proteinuria secondary to amyloidosis requiring bilateral renal artery embolization. Case Rep Nephrol Urol. 2:78–82. DOI: 10.1159/000339895. PMID: 23197960. PMCID: PMC3482077.

29. Friedman AN. 2004; High-protein diets: potential effects on the kidney in renal health and disease. Am J Kidney Dis. 44:950–62. DOI: 10.1053/j.ajkd.2004.08.020. PMID: 15558517.

30. Pinney JH, Lachmann HJ, Bansi L, et al. 2011; Outcome in renal AL amyloidosis after chemotherapy. J Clin Oncol. 29:674–81. DOI: 10.1200/JCO.2010.30.5235. PMID: 21220614.

31. Palladini G, Hegenbart U, Milani P, et al. 2014; A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood. 124:2325–32. DOI: 10.1182/blood-2014-04-570010. PMID: 25115890.

32. Moroni G, Banfi G, Montoli A, et al. 1992; Chronic dialysis in patients with systemic amyloidosis: the experience in northern Italy. Clin Nephrol. 38:81–5. PMID: 1516284.

33. Kagan A, Bar-Khayim Y. 1995; Role of peritoneal loss of albumin in the hypoalbuminemia of continuous ambulatory peritoneal dialysis patients: relationship to peritoneal transport of solutes. Nephron. 71:314–20. DOI: 10.1159/000188738. PMID: 8569981.

34. Gertz MA, Kyle RA, O'Fallon WM. 1992; Dialysis support of patients with primary systemic amyloidosis. A study of 211 patients. Arch Intern Med. 152:2245–50. DOI: 10.1001/archinte.1992.00400230061010. PMID: 1444684.

35. Sattianayagam PT, Gibbs SD, Pinney JH, et al. 2010; Solid organ transplantation in AL amyloidosis. Am J Transplant. 10:2124–31. DOI: 10.1111/j.1600-6143.2010.03227.x. PMID: 20883547.

36. Herrmann SM, Gertz MA, Stegall MD, et al. 2011; Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation. Nephrol Dial Transplant. 26:2032–6. DOI: 10.1093/ndt/gfr067. PMID: 21543655.

37. Angel-Korman A, Stern L, Sarosiek S, et al. 2019; Long-term outcome of kidney transplantation in AL amyloidosis. Kidney Int. 95:405–11. DOI: 10.1016/j.kint.2018.09.021. PMID: 30580886.

38. Sathick IJ, Rosenbaum CA, Gutgarts V, Landau H. 2020; Kidney transplantation in AL amyloidosis: is it time to maximize access? Br J Haematol. 188:e1–4. DOI: 10.1111/bjh.16246. PMID: 31730739.

39. Chaulagain CP, Diacovo JM, Elson L, et al. 2020; Daratumumab-based regimen in treating clonal plasma cell neoplasms in solid organ transplant recipients. Clin Lymphoma Myeloma Leuk. 20:e137–43. DOI: 10.1016/j.clml.2019.12.022. PMID: 32029395. PMCID: PMC8183688.

40. Ow SY, Dunstan DE. 2014; A brief overview of amyloids and Alzheimer's disease. Protein Sci. 23:1315–31. DOI: 10.1002/pro.2524. PMID: 25042050. PMCID: PMC4286994.

41. Freeman R, Abuzinadah AR, Gibbons C, Jones P, Miglis MG, Sinn DI. 2018; Orthostatic hypotension: JACC state-of-the-art review. J Am Coll Cardiol. 72:1294–309. DOI: 10.1016/j.jacc.2018.05.079. PMID: 30190008.

42. Weber N, Mollee P, Augustson B, et al. 2015; Management of systemic AL amyloidosis: recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group. Intern Med J. 45:371–82. DOI: 10.1111/imj.12566. PMID: 25169210.

43. Freeman R. 2008; Clinical practice. Neurogenic orthostatic hypotension. N Engl J Med. 358:615–24. DOI: 10.1056/NEJMcp074189. PMID: 18256396.

44. Andrade MJ. 2009; Lower urinary tract dysfunction in familial amyloidotic polyneuropathy, Portuguese type. Neurourol Urodyn. 28:26–32. DOI: 10.1002/nau.20600. PMID: 19089892.

45. Burakgazi AZ, Alsowaity B, Burakgazi ZA, Unal D, Kelly JJ. 2012; Bladder dysfunction in peripheral neuropathies. Muscle Nerve. 45:2–8. DOI: 10.1002/mus.22178. PMID: 22190298.

46. Wixner J, Suhr OB, Anan I. 2018; Management of gastrointestinal complications in hereditary transthyretin amyloidosis: a single- center experience over 40 years. Expert Rev Gastroenterol Hepatol. 12:73–81. DOI: 10.1080/17474124.2018.1397511. PMID: 29073801.

47. Rubinow A, Burakoff R, Cohen AS, Harris LD. 1983; Esophageal manometry in systemic amyloidosis. A study of 30 patients. Am J Med. 75:951–6. DOI: 10.1016/0002-9343(83)90874-4. PMID: 6650550.

48. Battle WM, Rubin MR, Cohen S, Snape WJ Jr. 1979; Gastrointestinal- motility dysfunction in amyloidosis. N Engl J Med. 301:24–5. DOI: 10.1056/NEJM197907053010105. PMID: 221808.

49. Menke DM, Kyle RA, Fleming CR, Wolfe JT 3rd, Kurtin PJ, Oldenburg WA. 1993; Symptomatic gastric amyloidosis in patients with primary systemic amyloidosis. Mayo Clin Proc. 68:763–7. DOI: 10.1016/S0025-6196(12)60634-X. PMID: 8331978.

50. Park MA, Mueller PS, Kyle RA, Larson DR, Plevak MF, Gertz MA. 2003; Primary (AL) hepatic amyloidosis: clinical features and natural history in 98 patients. Medicine (Baltimore). 82:291–8. DOI: 10.1097/01.md.0000091183.93122.c7. PMID: 14530778.

51. Gertz MA, Lacy MQ, Dispenzieri A. 2004; Therapy for immunoglobulin light chain amyloidosis: the new and the old. Blood Rev. 18:17–37. DOI: 10.1016/S0268-960X(03)00027-4. PMID: 14684147.

52. Yam LT, Oropilla SB. 1991; Octreotide for diarrhea in amyloidosis. Ann Intern Med. 115:577. DOI: 10.7326/0003-4819-115-7-577_1. PMID: 1883131.

53. Rives S, Pera M, Rosiñol L, et al. 2002; Primary systemic amyloidosis presenting as a colonic stricture: successful treatment with left hemicolectomy followed by autologous hematopoietic stem-cell transplantation. Dis Colon Rectum. 45:1263–6. DOI: 10.1007/s10350-004-6403-x. PMID: 12352247.

54. Ek BO, Holmlund DE, Sjödin JG, Steen LE. 1978; Enterostomy in patients with primary neuropathic amyloidosis. Am J Gastroenterol. 70:365–70. PMID: 83105.

55. Berk JL, O'Regan A, Skinner M. 2002; Pulmonary and tracheobronchial amyloidosis. Semin Respir Crit Care Med. 23:155–65. DOI: 10.1055/s-2002-25304. PMID: 16088608.

56. Baumgart JV, Stuhlmann-Laeisz C, Hegenbart U, et al. 2018; Local vs. systemic pulmonary amyloidosis-impact on diagnostics and clinical management. Virchows Arch. 473:627–37. DOI: 10.1007/s00428-018-2442-x. PMID: 30136180.

57. Kurrus JA, Hayes JK, Hoidal JR, Menendez MM, Elstad MR. 1998; Radiation therapy for tracheobronchial amyloidosis. Chest. 114:1489–92. DOI: 10.1378/chest.114.5.1489. PMID: 9824038.

58. Fiorelli A, Accardo M, Galluccio G, Santini M. 2013; Tracheobronchial amyloidosis treated by endobronchial laser resection and self expanding Y stent. Arch Bronconeumol. 49:303–5. DOI: 10.1016/j.arbres.2012.11.013. PMID: 23474207.

59. Ericson S, Shah N, Liberman J, Aboulafia DM. 2014; Fatal bleeding due to acquired factor IX and X deficiency: a rare complication of primary amyloidosis; case report and review of the literature. Clin Lymphoma Myeloma Leuk. 14:e81–6. DOI: 10.1016/j.clml.2013.08.007. PMID: 24290671.

60. McPherson RA, Onstad JW, Ugoretz RJ, Wolf PL. 1977; Coagulopathy in amyloidosis: combined deficiency of factors IX and X. Am J Hematol. 3:225–35. DOI: 10.1002/ajh.2830030303. PMID: 602938.

61. Gertz MA, Lacy MQ, Dispenzieri A. 1999; Amyloidosis: recognition, confirmation, prognosis, and therapy. Mayo Clin Proc. 74:490–4. DOI: 10.1016/S0025-6196(11)65130-6. PMID: 10319082.

62. Thompson CA, Kyle R, Gertz M, Heit J, Pruthi R, Pardanani A. 2010; Systemic AL amyloidosis with acquired factor X deficiency: a study of perioperative bleeding risk and treatment outcomes in 60 patients. Am J Hematol. 85:171–3. DOI: 10.1002/ajh.21603. PMID: 20052750. PMCID: PMC2896569.

63. Boggio L, Green D. 2001; Recombinant human factor VIIa in the management of amyloid-associated factor X deficiency. Br J Haematol. 112:1074–5. DOI: 10.1046/j.1365-2141.2001.02667.x. PMID: 11298609.

64. Veneri D, Giuffrida AC, Bonalumi A, et al. 2016; Use of prothrombin complex concentrate for prophylaxis of bleeding in acquired factor X deficiency associated with light-chain amyloidosis. Blood Transfus. 14:585–6. DOI: 10.2450/2016.0335-15. PMID: 27416580. PMCID: PMC5111391.

65. Litvak A, Kumar A, Wong RJ, Smith L, Hassou H, Soff G. 2014; Successful perioperative use of prothrombin complex concentrate in the treatment of acquired factor X deficiency in the setting of systemic light-chain (AL) amyloidosis. Am J Hematol. 89:1153–4. DOI: 10.1002/ajh.23813. PMID: 25060940.

66. Mahmood S, Blundell J, Drebes A, Hawkins PN, Wechalekar AD. 2014; Utility of factor X concentrate for the treatment of acquired factor X deficiency in systemic light-chain amyloidosis. Blood. 123:2899–900. DOI: 10.1182/blood-2014-02-556514. PMID: 24786460.

67. Greipp PR, Kyle RA, Bowie EJ. 1979; Factor X deficiency in primary amyloidosis: resolution after splenectomy. N Engl J Med. 301:1050–1. DOI: 10.1056/NEJM197911083011907. PMID: 492235.

68. Rosenstein ED, Itzkowitz SH, Penziner AS, Cohen JI, Mornaghi RA. 1983; Resolution of factor X deficiency in primary amyloidosis following splenectomy. Arch Intern Med. 143:597–9. DOI: 10.1001/archinte.1983.00350030211041. PMID: 6830397.

69. Böhrer H, Waldherr R, Martin E, et al. 1998; Splenectomy in an uraemic patient with acquired factor X deficiency due to AL amyloidosis. Nephrol Dial Transplant. 13:190–3. DOI: 10.1093/ndt/13.1.190. PMID: 9481739.

70. Lin HM, Seldin D, Hui AM, Berg D, Dietrich CN, Flood E. 2015; The patient's perspective on the symptom and everyday life impact of AL amyloidosis. Amyloid. 22:244–51. DOI: 10.3109/13506129.2015.1102131. PMID: 26587688.

71. Lousada I, Comenzo RL, Landau H, Guthrie S, Merlini G. 2015; Light chain amyloidosis: patient experience survey from the amyloidosis research consortium. Adv Ther. 32:920–8. DOI: 10.1007/s12325-015-0250-0. PMID: 26498944. PMCID: PMC4635176.

72. Prokaeva T, Spencer B, Kaut M, et al. 2007; Soft tissue, joint, and bone manifestations of AL amyloidosis: clinical presentation, molecular features, and survival. Arthritis Rheum. 56:3858–68. DOI: 10.1002/art.22959. PMID: 17968927.

73. Muchtar E, Derudas D, Mauermann M, et al. 2016; Systemic immunoglobulin light chain amyloidosis-associated myopathy: presentation, diagnostic pitfalls, and outcome. Mayo Clin Proc. 91:1354–61. DOI: 10.1016/j.mayocp.2016.06.027. PMID: 27712634.

74. Vivino FB. 2017; Sjogren's syndrome: clinical aspects. Clin Immunol. 182:48–54. DOI: 10.1016/j.clim.2017.04.005. PMID: 28428095.

75. Jacobs P, Sellars S, King HS. 1988; Massive macroglossia, amyloidosis and myeloma. Postgrad Med J. 64:696–8. DOI: 10.1136/pgmj.64.755.696. PMID: 3150784. PMCID: PMC2428968.

76. Thibault I, Vallières I. 2011; Macroglossia due to systemic amyloidosis: is there a role for radiotherapy? Case Rep Oncol. 4:392–9. DOI: 10.1159/000330238. PMID: 21941488. PMCID: PMC3177795.

77. Eder L, Bitterman H. 2007; Image in clinical medicine. Amyloid purpura. N Engl J Med. 356:2406. DOI: 10.1056/NEJMicm061510. PMID: 17554122.

78. Westermark P, Ohman S, Domar M, Sletten K. 1981; Bullous amyloidosis. Arch Dermatol. 117:782–4. DOI: 10.1001/archderm.1981.01650120028015. PMID: 7032426.

79. Elsaman AM, Radwan AR, Akmatov MK, et al. 2013; Amyloid arthropathy associated with multiple myeloma: a systematic analysis of 101 reported cases. Semin Arthritis Rheum. 43:405–12. DOI: 10.1016/j.semarthrit.2013.07.004. PMID: 23992800.